Hypoxia increases vasodilator release from internal mammary artery and saphenous vein grafts

Paul J. Pearson, Paulo R B Evora, Berent Discigil, Hartzell V Schaff

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background. Greater release of endothelium-derived nitric oxide is implicated in the superior patency of the internal mammary artery (IMA) used in coronary artery bypass grafting. This study compared the release of endothelium-derived nitric oxide into the lumen of the IMA and the saphenous vein under normoxic versus hypoxic conditions. Methods. Segments of canine IMA and saphenous vein were perfused in vitro. Vasorelaxant activity was measured as vasodilatation of coronary artery smooth muscle induced by the effluent. Results. Effluents from the IMA and saphenous vein caused comparable vasodilatation of coronary artery smooth muscle. The vasodilatation reversed when perfusion was switched to a prosthetic conduit. Vasodilator activity from the IMA and saphenous vein was attenuated by removing the intima of the grafts or by adding N(G)-monomethyl-L-arginine (10-4 mol/L) or N(G)-nitro-L-arginine (10-4 mol/L), two inhibitors of nitric oxide synthesis. Indomethacin attenuated vasorelaxant activity from saphenous vein grafts but not IMA grafts (n = 10). Vasodilator release from the IMA and saphenous vein was augmented by hypoxia. This augmentation was inhibited by indomethacin (n = 10, p < 0.05). Hypoxic augmentation reversed with return to normoxia. Conclusions. The release of endothelium-derived nitric oxide and prostacyclin from bypass grafts into the lumen, particularly during hypoxemia, could promote the vasodilatation of distal coronary arterial beds, enhancing myocardial perfusion.

Original languageEnglish (US)
Pages (from-to)1220-1225
Number of pages6
JournalAnnals of Thoracic Surgery
Volume65
Issue number5
DOIs
StatePublished - May 1998

Fingerprint

Mammary Arteries
Saphenous Vein
Vasodilator Agents
Transplants
Vasodilation
Nitric Oxide
Indomethacin
Smooth Muscle
Arginine
Coronary Vessels
Perfusion
Epoprostenol
Hypoxia
Coronary Artery Bypass
Canidae

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Hypoxia increases vasodilator release from internal mammary artery and saphenous vein grafts. / Pearson, Paul J.; Evora, Paulo R B; Discigil, Berent; Schaff, Hartzell V.

In: Annals of Thoracic Surgery, Vol. 65, No. 5, 05.1998, p. 1220-1225.

Research output: Contribution to journalArticle

Pearson, Paul J. ; Evora, Paulo R B ; Discigil, Berent ; Schaff, Hartzell V. / Hypoxia increases vasodilator release from internal mammary artery and saphenous vein grafts. In: Annals of Thoracic Surgery. 1998 ; Vol. 65, No. 5. pp. 1220-1225.
@article{ae2fa7e57f2049fba7a38bbcea0af5b8,
title = "Hypoxia increases vasodilator release from internal mammary artery and saphenous vein grafts",
abstract = "Background. Greater release of endothelium-derived nitric oxide is implicated in the superior patency of the internal mammary artery (IMA) used in coronary artery bypass grafting. This study compared the release of endothelium-derived nitric oxide into the lumen of the IMA and the saphenous vein under normoxic versus hypoxic conditions. Methods. Segments of canine IMA and saphenous vein were perfused in vitro. Vasorelaxant activity was measured as vasodilatation of coronary artery smooth muscle induced by the effluent. Results. Effluents from the IMA and saphenous vein caused comparable vasodilatation of coronary artery smooth muscle. The vasodilatation reversed when perfusion was switched to a prosthetic conduit. Vasodilator activity from the IMA and saphenous vein was attenuated by removing the intima of the grafts or by adding N(G)-monomethyl-L-arginine (10-4 mol/L) or N(G)-nitro-L-arginine (10-4 mol/L), two inhibitors of nitric oxide synthesis. Indomethacin attenuated vasorelaxant activity from saphenous vein grafts but not IMA grafts (n = 10). Vasodilator release from the IMA and saphenous vein was augmented by hypoxia. This augmentation was inhibited by indomethacin (n = 10, p < 0.05). Hypoxic augmentation reversed with return to normoxia. Conclusions. The release of endothelium-derived nitric oxide and prostacyclin from bypass grafts into the lumen, particularly during hypoxemia, could promote the vasodilatation of distal coronary arterial beds, enhancing myocardial perfusion.",
author = "Pearson, {Paul J.} and Evora, {Paulo R B} and Berent Discigil and Schaff, {Hartzell V}",
year = "1998",
month = "5",
doi = "10.1016/S0003-4975(98)00096-4",
language = "English (US)",
volume = "65",
pages = "1220--1225",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Hypoxia increases vasodilator release from internal mammary artery and saphenous vein grafts

AU - Pearson, Paul J.

AU - Evora, Paulo R B

AU - Discigil, Berent

AU - Schaff, Hartzell V

PY - 1998/5

Y1 - 1998/5

N2 - Background. Greater release of endothelium-derived nitric oxide is implicated in the superior patency of the internal mammary artery (IMA) used in coronary artery bypass grafting. This study compared the release of endothelium-derived nitric oxide into the lumen of the IMA and the saphenous vein under normoxic versus hypoxic conditions. Methods. Segments of canine IMA and saphenous vein were perfused in vitro. Vasorelaxant activity was measured as vasodilatation of coronary artery smooth muscle induced by the effluent. Results. Effluents from the IMA and saphenous vein caused comparable vasodilatation of coronary artery smooth muscle. The vasodilatation reversed when perfusion was switched to a prosthetic conduit. Vasodilator activity from the IMA and saphenous vein was attenuated by removing the intima of the grafts or by adding N(G)-monomethyl-L-arginine (10-4 mol/L) or N(G)-nitro-L-arginine (10-4 mol/L), two inhibitors of nitric oxide synthesis. Indomethacin attenuated vasorelaxant activity from saphenous vein grafts but not IMA grafts (n = 10). Vasodilator release from the IMA and saphenous vein was augmented by hypoxia. This augmentation was inhibited by indomethacin (n = 10, p < 0.05). Hypoxic augmentation reversed with return to normoxia. Conclusions. The release of endothelium-derived nitric oxide and prostacyclin from bypass grafts into the lumen, particularly during hypoxemia, could promote the vasodilatation of distal coronary arterial beds, enhancing myocardial perfusion.

AB - Background. Greater release of endothelium-derived nitric oxide is implicated in the superior patency of the internal mammary artery (IMA) used in coronary artery bypass grafting. This study compared the release of endothelium-derived nitric oxide into the lumen of the IMA and the saphenous vein under normoxic versus hypoxic conditions. Methods. Segments of canine IMA and saphenous vein were perfused in vitro. Vasorelaxant activity was measured as vasodilatation of coronary artery smooth muscle induced by the effluent. Results. Effluents from the IMA and saphenous vein caused comparable vasodilatation of coronary artery smooth muscle. The vasodilatation reversed when perfusion was switched to a prosthetic conduit. Vasodilator activity from the IMA and saphenous vein was attenuated by removing the intima of the grafts or by adding N(G)-monomethyl-L-arginine (10-4 mol/L) or N(G)-nitro-L-arginine (10-4 mol/L), two inhibitors of nitric oxide synthesis. Indomethacin attenuated vasorelaxant activity from saphenous vein grafts but not IMA grafts (n = 10). Vasodilator release from the IMA and saphenous vein was augmented by hypoxia. This augmentation was inhibited by indomethacin (n = 10, p < 0.05). Hypoxic augmentation reversed with return to normoxia. Conclusions. The release of endothelium-derived nitric oxide and prostacyclin from bypass grafts into the lumen, particularly during hypoxemia, could promote the vasodilatation of distal coronary arterial beds, enhancing myocardial perfusion.

UR - http://www.scopus.com/inward/record.url?scp=0032076017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032076017&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(98)00096-4

DO - 10.1016/S0003-4975(98)00096-4

M3 - Article

VL - 65

SP - 1220

EP - 1225

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -